The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results.
Andrew David Norden
No relevant relationships to disclose
Jan Drappatz
No relevant relationships to disclose
Surasak Phuphanich
No relevant relationships to disclose
David A. Reardon
No relevant relationships to disclose
Eric T. Wong
No relevant relationships to disclose
Scott Randall Plotkin
No relevant relationships to disclose
Thomas Joseph Kaley
No relevant relationships to disclose
Jeffrey J. Raizer
Consultant or Advisory Role - Genentech; Novartis
Honoraria - Genentech
Glenn Jay Lesser
No relevant relationships to disclose
Tracy Batchelor
No relevant relationships to disclose
Eudocia Quant Lee
No relevant relationships to disclose
Rameen Beroukhim
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Alona Muzikansky
No relevant relationships to disclose
Lisa M. Doherty
No relevant relationships to disclose
Debra C. LaFrankie
No relevant relationships to disclose
Sandra Ruland
No relevant relationships to disclose
Katrina H. Smith
No relevant relationships to disclose
Mary Gerard
No relevant relationships to disclose
Christine Sceppa McCluskey
No relevant relationships to disclose
Patrick Y. Wen
No relevant relationships to disclose